Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

Author： Koutras Angelos   Mastronikolis Nicholas   Jeffry Evans Tr   Papadeas Evangelos   Makatsoris Thomas   Kalofonos Haralabos  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.47, Iss.6, 2008-08, pp. : 1171-1173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib

By Lin Po-Chou  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 140-150

Humana Press, Inc

Access to resources Recommend Favorite

Erlotinib: In Advanced Pancreatic Cancer

By Simpson Dene   Scott Lesley J.   Noble Stuart  

American Journal of Cancer, Vol. 5, Iss. 1, 2006-01 ,pp. : 35-40

Adis International

Access to resources Recommend Favorite

Erlotinib or capecitabine with gemcitabine in pancreatic cancer?

By de Jager Jenny   Stebbing Justin  

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 161-163

Future Medicine

Access to resources Recommend Favorite

Pancreatic Cancer Epidermal Growth Factor Receptor ( EGFR ) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response

By Tzeng Ching-Wei   Frolov Andrey   Frolova Natalya   Jhala Nirag   Howard J.   Vickers Selwyn   Buchsbaum Donald   Heslin Martin   Arnoletti J.  

Annals of Surgical Oncology, Vol. 14, Iss. 7, 2007-07 ,pp. : 2150-2158

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib in Advanced Pancreatic Cancer: A Viewpoint by Andrew H. Ko

By Ko Andrew H.  

American Journal of Cancer, Vol. 5, Iss. 1, 2006-01 ,pp. : 41-42

Adis International

Access to resources Recommend Favorite